• 1
    Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
  • 2
    Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. ASCO Meeting Abstracts. 2012;30(15 Suppl):7508.
  • 3
    Ou S-HI, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de Novo MET amplification. J Thorac Oncol. 2011;6:942-946.
  • 4
    Shaw AT, Kim DW, Nagagawa K, Camidge DR, Solomon B. Phase III study of crizotinib vs. pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007). ESMO. 2012 (2862).
  • 5
    Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2012;30(15 Suppl):7533.
  • 6
    Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012;9:258-277.
  • 7
    Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. Sep 3 2012.
  • 8
    Weickhardt AJ, Camidge DR. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin Investig. 2011;1:1119-1126.
  • 9
    Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-4253.
  • 10
    Weickhardt AJ, Rothman MS, Salian-Mehta S, et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012;118:5302-5309.
  • 11
    Ramalingam SS, Shaw AT. Hypogonadism related to crizotinib therapy: Implications for patient care. Cancer. 2012;118:E1-E2.
  • 12
    Lemieux L, Kaiser S, Pereira J, Meadows LM. Sexuality in palliative care: patient perspectives. Palliat Med. 2004;18:630-637.
  • 13
    Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239-1242.
  • 14
    Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol. 2007;67:853-862.
  • 15
    Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001;7:363-369.
  • 16
    Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res. 1982;42:2495-2498.
  • 17
    Sperti C, Bonadimani B, Guolo P, et al. Androgen profile in patients with pancreatic carcinoma. Ital J Gastroenterol. 1992;24:328-331.
  • 18
    Burney B, Garcia J. Hypogonadism in male cancer patients. J Cachexia, Sarcopenia Muscle. 2012;3:149-155.
  • 19
    Petitpas I, Bhattacharya AA, Twine S, East M, Curry S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site i. J Biol Chem. 2001;276:22804-22809.
  • 20
    Costa DB, Kobayashi S, Pandya SS, et al. CSF Concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443-e445.
  • 21
    Risau W, Wolburg H. Development of the blood-brain barrier. Trends Neurosci. 1990;13:174-178.
  • 22
    Mehra R, Camidge DR, Sharma S, et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. ASCO Meeting Abstracts. 2012;30(15 Suppl):3007.
  • 23
    Gettinger S, Weiss GJ, Salgia R, et al. A first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. ESMO 37th Annual Meeting 2012; Abstract 4390.
  • 24
    Diver MJ; Clinical Science Reviews Committee of the Association for Clinical Biochemistry. Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Ann Clin Biochem. 2006;43:3-12.
  • 25
    Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer. 1986;58:183-186.
  • 26
    Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf). 2001;55:315-324.
  • 27
    Mosse YP, Balis FM, Lim MS, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. ASCO Meeting Abstracts. 2012;30(15 Suppl):9500.